Photorefraction Screening Plus Atropine Treatment for Myopia is Cost-Effective: A Proof-of-Concept Markov Analysis.

Chuen Yen Hong Matthew J BoydGraham WilsonSheng Chiong Hong

Published in: Clinical ophthalmology (Auckland, N.Z.) (2022)

Screening for myopia with photorefraction at age 11 and atropine 0.01% eye drop treatment of children screening positive is likely to be cost-effective. These results suggest that a real-world trial and cost-effectiveness analysis would be worth considering in New Zealand.

Keyphrases

young adults
clinical trial
randomized controlled trial
combination therapy
phase ii
data analysis
smoking cessation